相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sulfated glycolipid PG545 induces endoplasmic reticulum stress and augments autophagic flux by enhancing anticancer chemotherapy efficacy in endometrial cancer
Robert Hoffmann et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Regulation and pharmacological targeting of RAD51 in cancer
McKenzie K. Grundy et al.
NAR CANCER (2020)
Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
Alanna R. Kaplan et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors
Silvia Maifrede et al.
BLOOD (2018)
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours
Keith Dredge et al.
BRITISH JOURNAL OF CANCER (2018)
Quinacrine upregulates p21/p27 independent of p53 through autophagy-mediated downregulation of p62-Skp2 axis in ovarian cancer
DeokBeom Jung et al.
SCIENTIFIC REPORTS (2018)
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors
Edward Hammond et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival
Kari E. Hacker et al.
NEOPLASIA (2018)
DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma
Jie Sun et al.
ONCOLOGY REPORTS (2017)
DEK is required for homologous recombination repair of DNA breaks
Eric A. Smith et al.
SCIENTIFIC REPORTS (2017)
The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression1
Preeti Singh et al.
NEOPLASIA (2017)
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit et al.
CLINICAL CANCER RESEARCH (2017)
Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation
Todd V. Brennan et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma
Xin Liu et al.
ONCOLOGY REPORTS (2016)
Combenefit: an interactive platform for the analysis and visualization of drug combinations
Giovanni Y. Di Veroli et al.
BIOINFORMATICS (2016)
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Yvette Drew et al.
BRITISH JOURNAL OF CANCER (2016)
CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma
Josephine Walton et al.
CANCER RESEARCH (2016)
Overexpression of DEK is an indicator of poor prognosis in patients with gastric adenocarcinoma
Yingfu Ou et al.
ONCOLOGY LETTERS (2016)
PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples
Boris Winterhoff et al.
EUROPEAN JOURNAL OF CANCER (2015)
AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer
David Pepin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine
Deok-Beom Jung et al.
ONCOTARGET (2015)
Quinacrine promotes autophagic cell death and chemosensitivity in ovarian cancer and attenuates tumor growth
Ashwani Khurana et al.
ONCOTARGET (2015)
The human oncoprotein and chromatin architectural factor DEK counteracts DNA replication stress
A. Deutzmann et al.
ONCOGENE (2015)
Heparan sulfate proteoglycan as a cell-surface endocytosis receptor
Helena C. Christianson et al.
MATRIX BIOLOGY (2014)
PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer
Katherine T. Ostapoff et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Intercellular trafficking of the nuclear oncoprotein DEK
Anjan K. Saha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
PG545, a Heparan Sulfate Mimetic, Reduces Heparanase Expression In Vivo, Blocks Spontaneous Metastases and Enhances Overall Survival in the 4T1 Breast Carcinoma Model
Edward Hammond et al.
PLOS ONE (2012)
PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
K. Dredge et al.
BRITISH JOURNAL OF CANCER (2011)
High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome
Raffaela Barbano et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
The human DEK oncogene regulates DNA damage response signaling and repair
Gina M. Kavanaugh et al.
NUCLEIC ACIDS RESEARCH (2011)
The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy
K. Dredge et al.
INVESTIGATIONAL NEW DRUGS (2010)
The consequences of Rad51 overexpression for normal and tumor cells
Hannah L. Klein
DNA REPAIR (2008)
The DEK nuclear autoantigen is a secreted chemotactic factor
Nirit Mor-Vaknin et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
The comet assay: a method to measure DNA damage in individual cells
Peggy L. Olive et al.
NATURE PROTOCOLS (2006)
分享论文
